Data and Safety Monitoring is a required service provided to Center Investigators. The SKCCC Data and Safety Monitoring Plan (DSMP) outlines all of the steps taken to ensure overall high quality of research data and protection of research participants. The Plan is implemented and coordinated by the Clinical Research Office Quality Assurance Team. The QA team is responsible for 1) auditing and monitoring clinical trials to assure compliance with protocol treatment, measurement of effect, and adherence to regulatory requirements, (auditing is the periodic review of a representative sample of the data from a trial;monitoring is the continuous, ongoing review of the conduct of the trial), 2) supplying data to the Data and Safety Monitoring Committee (DSMC) and ensuring Committee recommendations are followed, 3) coordinating the Data and Safety Monitoring Board (DSMB) and ensuring Board recommendations are followed, 4) providing regulatory guidance to Pis and study staff, 5) developing and implementing Standard Operating Procedures, 6) serving as a liaison with external regulatory agencies, 7) coordinating and implementing the Institution's regulatory changes, and 8) reviewing protocols for completeness, consistency, errors, and acheivability of protocol evaluations in the CRC pre-review Committee. The ultimate responsibility for data and safety monitoring resides with the DSMC. The DSMC is responsible for assuring adherence to study design and patient safety by reviewing internal and external auditing and monitoring reports and reviewing serious adverse events. The DSMC has the ability to close a trial or mandate changes, as well as, make policy recommendations that may improve the quality of data or improve patient safety within the Center. These policy recommendations are submitted to the Clinical Research Operations Committee for possible implementation. In this Core, we are requesting effort only for monitoring related to supporting the DSMC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-47
Application #
7821302
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-05-01
Budget End
2010-04-30
Support Year
47
Fiscal Year
2009
Total Cost
$105,085
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Dean, Lorraine T; Montgomery, Madeline C; Raifman, Julia et al. (2018) The Affordability of Providing Sexually Transmitted Disease Services at a Safety-net Clinic. Am J Prev Med 54:552-558
Bastos, Diogo A; Antonarakis, Emmanuel S (2018) AR-V7 and treatment selection in advanced prostate cancer: are we there yet? Precis Cancer Med 1:
Stein-O'Brien, Genevieve; Kagohara, Luciane T; Li, Sijia et al. (2018) Integrated time course omics analysis distinguishes immediate therapeutic response from acquired resistance. Genome Med 10:37
Brundage, Michael; Blackford, Amanda; Tolbert, Elliott et al. (2018) Presenting comparative study PRO results to clinicians and researchers: beyond the eye of the beholder. Qual Life Res 27:75-90
Mondul, Alison M; Joshu, Corinne E; Barber, John R et al. (2018) Longer-term Lipid-lowering Drug Use and Risk of Incident and Fatal Prostate Cancer in Black and White Men in the ARIC Study. Cancer Prev Res (Phila) 11:779-788
Lu, Dai-Yin; Yalçin, Hulya; Yalçin, Fatih et al. (2018) Stress Myocardial Blood Flow Heterogeneity Is a Positron Emission Tomography Biomarker of Ventricular Arrhythmias in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol 121:1081-1089
Gordy, James T; Luo, Kun; Francica, Brian et al. (2018) Anti-IL-10-mediated Enhancement of Antitumor Efficacy of a Dendritic Cell-targeting MIP3?-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I Interferons. J Immunother 41:181-189
Woodard, Lauren E; Dennis, Cindi L; Borchers, Julie A et al. (2018) Nanoparticle architecture preserves magnetic properties during coating to enable robust multi-modal functionality. Sci Rep 8:12706
Shrestha, Eva; White, James R; Yu, Shu-Han et al. (2018) Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer. J Urol 199:161-171
Christenson, Eric S; Antonarakis, Emmanuel S (2018) PARP inhibitors for homologous recombination-deficient prostate cancer. Expert Opin Emerg Drugs 23:123-133

Showing the most recent 10 out of 2393 publications